[ad_1]
Dublin, December 31, 2021 /PRNewswire/– “Investigation Report” China’s Docetaxel Market 2021-2025″ Report has been added to ResearchAndMarkets.com supply.
According to market research, sales of docetaxel in the Chinese market remained unchanged from 2016 to 2019. China’s The overall diagnosis and treatment services of the hospital, the sales of docetaxel in the Chinese market dropped to RMB 1.112 billion The year-on-year decrease of 16.79% in 2020. From 2016 to 2020, the compound annual growth rate of sales of docetaxel in the Chinese market is -3.86%.
Docetaxel, sold under the trade name Taxotere, is a paclitaxel anti-tumor drug used to treat locally advanced or metastatic non-small cell lung cancer. Docetaxel injection was first developed and produced by the French company Rhone Planck Lean (later renamed Aventis, also known as Sanofi-Aventis).It was approved by the European Union for the first time in 1995. China From 1996 to 2020, there have been many manufacturers in the Chinese docetaxel market.
Analysts predict that as the COVID-19 epidemic eases, Docetaxel’s sales will show a recovery growth from 2021-2025. In addition, there were 4.57 million new cancer cases. China By 2020, the overall cancer incidence will increase by approximately 3.9% per year.
Therefore, sales of docetaxel for the treatment of locally advanced or metastatic non-small cell lung cancer will increase…
The full story can be found on Benzinga.com
[ad_2]
Source link
